The Effect of TRADJENTA (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Nov 2017 Planned End Date changed from 1 Aug 2016 to 1 May 2018.
- 02 Nov 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2018.
- 02 Nov 2017 Status changed from recruiting to active, no longer recruiting.